Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006

Canadian Journal of Cardiology

Volumn 24, Issue 6, 2008, Pages 507-512

  Hemmelgarn, Brenda R ^a,b,f   Chen, Guanmin ^b   Walker, Robin ^b   McAlister, Finlay A ^c   Quan, Hude ^a   Tu, Karen ^d   Khan, Nadia ^e   Campbell, Norm ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f FOOTHILLS HOSPITAL   (Canada)

Author keywords

Drug therapy; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; FOSINOPRIL; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; METOLAZONE; METOPROLOL; NADOLOL; NIFEDIPINE; NIMODIPINE; NITRIC ACID DERIVATIVE; PINDOLOL; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; RAMIPRIL; SOTALOL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ADULT; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE REGULATION; CANADA; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG UTILIZATION; FACTUAL DATABASE; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; TIME SERIES ANALYSIS; TREND STUDY; AGED; COMPARATIVE STUDY; MIDDLE AGED; PATIENT COMPLIANCE; PREVALENCE; RETROSPECTIVE STUDY; STATISTICS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CANADA; HUMANS; HYPERTENSION; MIDDLE AGED; OFFICE VISITS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 46249089536     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70627-5     Document Type: Article

References (22)

1. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-7.
2. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996;275:1571-6.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13. (Erratum in 2003;361:1060).
4. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
5. McAlister FA. The Canadian Hypertension Education Program - a unique Canadian initiative. Can J Cardiol 2006;22:559-64.
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
8. ALLHAT Officers & Coordinators. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
9. McAlister FA, Zarnke KB, Campbell NR, et al; Canadian Hypertension Recommendations Working Group. The 2001 Canadian recommendations for the management of hypertension: Part two - therapy. Can J Cardiol 2002;18:625-41.
10. Campbell NR, McAlister FA, Brant R, et al; Canadian Hypertension Education Process and Evaluation Committee, Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program. J Hypertens 2003;21:1591-7.
11. Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV; Canadian Cardiovascular Outcomes Research Team. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol 2003;19:1359-66.
12. Canadian Hypertension Recommendations Working Group. The 2001 Canadian hypertension recommendations. What is new and what is old but still important. Can J Cardiol 2002;18:591-603.
13. Tu K, Campbell NR, Duong-Hua M, McAlister FA. Hypertension management in the elderly has improved: Ontario prescribing trends, 1994 to 2002. Hypertension 2005;45:1113-8.
14. Majumdar SR, McAlister FA, Furberg CD. From knowledge to practice in chronic cardiovascular disease: A long and winding road. J Am Coll Cardiol 2004;43:1738-42.
15. Drouin D, Campbell NR, Kaczorowski J. Implementation of recommendations on hypertension: The Canadian Hypertension Education Program. Can J Cardiol 2006;22:595-8.
16. Campbell N, Onysko J; Canadian Hypertension Education Program; Outcomes Research Task Force. The Outcomes Research Task Force and the Canadian Hypertension Education Program. Can J Cardiol 2006;22:556-8.
17. Onysko J, Maxwell C, Eliasziw M, Zhang JX, Johansen H, Campbell NR; Canadian Hypertension Education Program. Large increases in hypertension diagnosis and treatment in Canada after a healthcare professional education program. Hypertension 2006;48:853-60.
18. Campbell NR, McAlister FA, Duong-Hua M, Tu K. Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement. Can J Cardiol 2007;23:783-7.
19. Leenen FH, Nwachuku CE, Black HR, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006;48:374-84.
20. Campbell NR, Tu K, Brant R, Duong-Hua M, McAlister FA; Canadian Hypertension Education Program Outcomes Research Task Force. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension 2006;47:22-8.
21. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
22. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007;120:713-9.